N/A N=105 SCS Programming Study in Treating Intractable Chronic Back Pain (NOVA)
Chronic Back Pain
Primary: Percentage of Subjects Who Respond to DTM-SCS Therapy Compared to Conventional SCS Therapy — 93.5; 36.4 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1,592 Southeastern Collaboration to Improve Blood Pressure Control
Hypertension
Primary: Number of Participants With Blood Pressure Control (Systolic Pressure Less Than 140 mm Hg and Diastolic Pressure Less Than 90 mm Hg) at 12 Months — 112; 87; 130; 92…
N/A N=11 Brain Targets in Patients With Bladder Emptying Difficulties
Neurogenic Bladder · Multiple Sclerosis · Voiding Dysfunction
Primary: Changes in Brain Activity After Treatment Measured Using Functional MRI — 2.759234; 3.423569; 3.000987; 3.094914 BOLD fMRI T-Value — p=<0.05
N/A N=12 Electrical Stimulation of the Dentate Nucleus for Upper Extremity Hemiparesis Due to Ischemic Stroke
Stroke
Primary: Adverse Events — 0 study-related, serious adverse events
Phase 4 N=110 CoolSculpting® Elite for Non-Invasive Fat Reduction
Non-invasive Fat Reduction
Primary: Percentage of Participants With "Satisfied" or "Very Satisfied" on Item #1 for the CSQ (Cryolipolysis Satisfaction Questionnaire) - Midsection — 83.3 percentage of…
N/A N=67 A Prospective, Multi-site Clinical Study to Collect User Feedback Using Affirm® Contrast Biopsy
Breast Cancer
Primary: Number of Participants With Technical Success — 60 Participants
N/A N=13 Wellness Achieved Through Changing Habits (The WATCH Study)
Weight Loss · Obesity · Overweight
Primary: Number of Participants Recruited — 16 Participants
Phase 4 N=17 Itraconazole Oral Absorption
Fungal Infection
Primary: AUC — 1624.8; 1365.5; 1282.2; 1848.7 ng*hr/mL
N/A N=31 Open-label MNS for Tourette Syndrome
Tourette Syndrome · Tic Disorder, Chronic Motor or Vocal
Primary: Time Spent Using the Device Per Day of Use — 49.6 minutes per day
N/A N=80 Engaging Rural Men With Mobile Technologies for Weight Loss
Weight Loss
Primary: Mean Change in Weight by Randomized Group — -7.03; -4.14 kilograms
Phase 2 N=153 Ecopipam Tablets to Study Tourette's Syndrome in Children and Adolescents
Tourette Syndrome
Primary: Change From Baseline in the Yale Global Tic Severity Scale-Total Tic Score (YGTSS-TTS) at Week 12 — -9.87; -6.42 score on a scale — p==0.011
Phase 3 N=176 Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
Mesothelioma
Primary: Response Rate — 12; 12 Participants — p=0.9489
Phase 2 N=276 Evaluation of the Efficacy and Safety of HTX-011 for Postoperative Analgesia Following Abdominoplasty Surgery
Postoperative Pain
Primary: Summed Pain Intensity Scores Collected Over 24 Hours — 92.60; 96.16 Units on a scale
N/A N=62 Medication Adherence Patterns in Rheumatic Diseases: A Behavioral Trial
Rheumatic Diseases · Gout · Adherence, Medication
Primary: Rate of Medication Adherence — 0.76; 0.79; 0.83 percentage of doses taken — p=0.78
N/A N=100 Pilot of Preemptive Pharmacogenetics in Medically Underserved Patients
Pharmacogenetic Testing
Primary: Change in Global Patient Treatment Satisfaction Measured by the Treatment Satisfaction Questionnaire for Medication (TSQM) — 59.9; 64.4 score on a scale — p=0.001